Patents by Inventor Emily Carla Dykhuizen

Emily Carla Dykhuizen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antiviral Compounds for Use in the Treatment of Coronavirus Infection
    Publication number: 20230192634
    Abstract: The invention provides a BAF complex modulating compound for use as a coronavirus antiviral; wherein the BAF complex modulating compound is of Formula (I):
    Type: Application
    Filed: December 20, 2022
    Publication date: June 22, 2023
    Inventors: Emily Carla Dykhuizen, Mart Matthias Lamers, Bartholomeus Leonardus Haagmans, Tokameh Mahmoudi
  • Methods for identifying and treating cancer patients
    Patent number: 10976320
    Abstract: Methods for identifying and treating cancer patients likely to respond to topoisomerase inhibitors or likely to fail to respond to topoisomerase inhibitors are provided. The methods take advantage of the newly discovered role of BAF complexes in decatenation of DNA by topoisomerase IIa. Cancer cells are frequently at least partly defective in BAF complex activity. Such cells are targeted for therapy using certain topoisomerase IIa inhibitors according to the disclosed methods of treatment. Therapy of such cells using other topoisomerase inhibitors should be avoided.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: April 13, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Emily Carla Dykhuizen, Diana Clare Hargreaves, Cigall Kadoch, Gerald R. Crabtree
  • METHODS FOR IDENTIFYING AND TREATING CANCER PATIENTS
    Publication number: 20150185221
    Abstract: Methods for identifying and treating cancer patients likely to respond to topoisomerase inhibitors or likely to fail to respond to topoisomerase inhibitors are provided. The methods take advantage of the newly discovered role of BAF complexes in decatenation of DNA by topoisomerase IIa. Cancer cells are frequently at least partly defective in BAF complex activity. Such cells are targeted for therapy using certain topoisomerase IIa inhibitors according to the disclosed methods of treatment. Therapy of such cells using other topoisomerase inhibitors should be avoided.
    Type: Application
    Filed: May 21, 2014
    Publication date: July 2, 2015
    Inventors: Emily Carla Dykhuizen, Diana Clare Hargreaves, Cigall Kadoch, Gerald R. Crabtree
  • INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE THWART MYCOBACTERIAL GROWTH
    Publication number: 20120316208
    Abstract: Compounds which inhibit microbial growth or attenuate the virulence of pathogen microorganisms. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity as inhibitors of microbial growth of microorganisms which contain this enzyme and particularly those microorganisms in which this enzyme is responsible for the incorporation of galactofuranose residues, particularly for uridine 5?-diphosphate (UDP) galactopyranose mutase. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity to attenuate virulence of pathogenic microorganisms, including mycobacteria.
    Type: Application
    Filed: August 21, 2012
    Publication date: December 13, 2012
    Inventors: Laura Lee KIESSLING, Emily Carla DYKHUIZEN, John F. MAY
  • Inhibitors of UDP-galactopyranose mutase thwart mycobacterial growth
    Patent number: 8273778
    Abstract: Compounds which inhibit microbial growth or attenuate the virulence of pathogen microorganisms. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity as inhibitors of microbial growth of microorganisms which contain this enzyme and particularly those microorganisms in which this enzyme is responsible for the incorporation of galactofuranose residues, particularly for uridine 5?-diphosphate (UDP) galactopyranose mutase. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity to attenuate virulence of pathogenic microorganisms, including mycobacteria.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: September 25, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Laura Lee Kiessling, Emily Carla Dykhuizen, John F. May
  • INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE THWART MYCOBACTERIAL GROWTH
    Publication number: 20100056586
    Abstract: Compounds which inhibit microbial growth or attenuate the virulence of pathogen microorganisms. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity as inhibitors of microbial growth of microorganisms which contain this enzyme and particularly those microorganisms in which this enzyme is responsible for the incorporation of galactofuranose residues, particularly for uridine 5?-diphosphate (UDP) galactopyranose mutase. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity to attenuate virulence of pathogenic microorganisms, including mycobacteria.
    Type: Application
    Filed: April 27, 2009
    Publication date: March 4, 2010
    Inventors: Laura Lee Kiessling, Emily Carla Dykhuizen, John F. May